did fda ban compounded semaglutide announces for weight loss drugs Compound versions of GLP-1 drugs
Description
Because it works on the same GLP-1 receptor, regulators will apply the same class warnings (pancreatitis, gallbladder issues, and a thyroid C-cell tumor warning from animal studies)
Side-effect profiles are broadly similar across the class: GI symptoms are most common and typically most pronounced during dose escalation
Education is critical to get the most out of your employee benefits
Its high fiber content alongside detoxifying properties can be irritating to the gut by over stimulating
Medication or surgery to break up gallstones may be necessary
